A perspective on molecular therapy in cholangiocarcinoma: present status and future directions-Reference-Cited by-同舟云学术

A perspective on molecular therapy in cholangiocarcinoma: present status and future directions

Published:2014-01 Issue:1 Volume:1 Page:143-157
ISSN:2045-0923
Container-title:Hepatic Oncology
language:en
Short-container-title:Hepatic Oncology

Author:

Andersen Jesper B¹²,Thorgeirsson Snorri S³

Affiliation:

1. Biotech Research & Innovation Centre, University of Copenhagen, DK-2200 Copenhagen, Denmark

2. National Cancer Institute, Laboratory of Experimental Carcinogenesis, NIH, Building 37, Room 4146A, 37 Convent Drive, Bethesda, MD 20892-4262, USA. .

3. National Cancer Institute, Laboratory of Experimental Carcinogenesis, NIH, Building 37, Room 4146A, 37 Convent Drive, Bethesda, MD 20892-4262, USA

Abstract

SUMMARY Cholangiocarcinoma (CCA) is an orphan cancer with limited understanding of its genetic and genomic pathogenesis. Typically, it is highly treatment-refractory and patient outcome is dismal. Currently, there are no approved therapeutics for CCA and surgical resection remains the only option with curative intent. Clinical trials are currently being performed in a mixed cohort of biliary tract cancers that includes intrahepatic CCA, extrahepatic/perihilar CCA, distal extrahepatic CCA, gallbladder carcinoma and, in rare cases, even pancreatic cancers. Today, clinical trials fail primarily because they are underpowered mixed cohorts and designed without intent to enrich for markers to optimize success for targeted therapy. This review aims to emphasize current clinical attempts for targeted therapy of CCA, as well as highlight promising new candidate pathways revealed by translational genomics.

Publisher

Future Medicine Ltd

Subject

Oncology,Hepatology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/hep.13.4

Reference127 articles.

1. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

2. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

3. Clinical diagnosis and staging of cholangiocarcinoma

4. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery

5. Classification, Diagnosis, and Management of Cholangiocarcinoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma;Hepatology;2018-06-12

2. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy;Molecular Carcinogenesis;2017-05-17

3. Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy;Current Drug Targets;2017-05-04

4. Uncommon Hepatobiliary Tumors;Textbook of Uncommon Cancer;2017-03-11

5. Advances in the molecular characterization of liver tumors;Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set;2017